“Altruism-driven research” (EA meets… plant pathology?)

Link post

I’m crossposting this paper because I thought the source was interesting, rather than because I think the work is especially relevant to top-priority cause areas.(Though ALLFED might disagree?)

It’s also nice to see that researchers in a variety of fields may find EA’s principles useful for the causes they work on.

While I’ll stop short of including a full PDF of the paper (not sure what the relevant laws are), I will note that Sci-Hub exists.

Abstract

Effective altruism is an ethical framework for identifying the greatest potential benefits from investments. Here we apply effective altruism concepts to maximize research benefits, in terms of priority stakeholders, pathosystems, and research questions and technologies.

Priority stakeholders for research benefits may include smallholder farmers who have not yet attained the minimal standards of the UN Sustainable Development Goals; these farmers would often have the most to gain from better crop disease management, if their management problems are tractable.

In wildlands, prioritization has been based on the risk of extirpating keystone species. Pathosystems may be prioritized based on yield and quality loss, and also factors such as whether replacement of efforts is unlikely, such as for orphan crops and orphan pathosystems. Research products that help build sustainable and resilient systems can be particularly beneficial. The “value of information” from research can be evaluated in epidemic networks and landscapes, to identify priority locations for both benefits to individuals and benefits to constrain regional epidemics.

As decision-making becomes more consolidated and data more networked in digital agricultural systems, the range of ethical considerations expands. Low likelihood but high damage scenarios, such as generalist doomsday pathogens, may be research priorities because of the extreme cost if they were to occur. Regional microbiomes constitute a commons, and avoiding the ‘tragedy of the microbiome commons’ may depend on shifting research products from ‘common pool goods’ to ‘public goods’ or other categories.

We provide suggestions for how individual researchers and funders may make altruism-driven research more effective.

Notes

I’m not familiar with any of the co-authors, who include plant pathologists, geneticists, and one philosopher.

The citations in the early discussion of EA are solid choices. I liked this excerpt:

Discussions of research ethics often stop short at defining what should not be done: plagiarizing, harassment, falsifying data, taking advantage of research subjects, etc. Effective altruism offers a perspective on how to use evidence about likely impacts to make research investments as beneficial as possible.

And:

Some may find the term ‘altruism’ misleading in the context of research priorities, since individuals and institutions have complex motivations for embarking on philanthropic projects, including access to resources, personal financial gain, publicity, and elevated standing or prestige in society. The point here is not a lack of benefit for the researcher, but to maximize the overall benefits to other people and other species. We acknowledge the peculiarity in our use of the term “altruism-driven research,” but the term is appropriate insofar as many of the concepts used to describe this form of research are borrowed directly from the effective altruism framework. Those who are squeamish about the term “altruism” in this context may consider altruism-driven research as “consequence-driven”.